Roland R Griffiths
Overview
Explore the profile of Roland R Griffiths including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
6455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DiRenzo D, Barrett F, Perin J, Darrah E, Christopher-Stine L, Griffiths R
Psychedelic Med (New Rochelle)
. 2025 Mar;
2(2):109-115.
PMID: 40051582
Background: Psilocybin is a psychedelic drug with potential therapeutic effects in patients with mood and substance use disorders. Little is known about its impact on the immune system. Methods: Multiplex...
2.
Xin Y, Griffiths R, Davis A
J Psychoactive Drugs
. 2025 Feb;
:1-8.
PMID: 39943916
An interesting aspect of entity encounters during psychedelic experiences is their ability to transform one's religious beliefs. However, little is known about sex differences in these transformations. This study investigates...
3.
Nayak S, White S, Hilbert S, Lowe M, Jackson H, Griffiths R, et al.
J Psychoactive Drugs
. 2024 May;
:1-10.
PMID: 38715376
Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind perception, 2) non-naturalistic beliefs, and 3) Atheist-Believer status...
4.
Levin A, Lancelotta R, Sepeda N, Gukasyan N, Nayak S, Wagener T, et al.
PLoS One
. 2024 Mar;
19(3):e0300501.
PMID: 38483940
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin...
5.
Barrett F, Zhou Y, Carbonaro T, Roberts J, Smith G, Griffiths R, et al.
Front Neuroergon
. 2024 Jan;
2:784576.
PMID: 38235248
Psilocybin (a serotonin 2A, or 5-HT, receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with...
6.
Mathai D, Hilbert S, Sepeda N, Strickland J, Griffiths R, Garcia-Romeu A
Psychedelic Med (New Rochelle)
. 2023 Dec;
1(4):241-252.
PMID: 38152462
Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically...
7.
Doss M, Samaha J, Barrett F, Griffiths R, de Wit H, Gallo D, et al.
Psychol Rev
. 2023 Dec;
131(2):523-562.
PMID: 38095937
Despite distinct classes of psychoactive drugs producing putatively unique states of consciousness, there is surprising overlap in terms of their effects on episodic memory and cognition more generally. Episodic memory...
8.
Nayak S, Jackson H, Sepeda N, Mathai D, So S, Yaffe A, et al.
Front Psychiatry
. 2023 Oct;
14:1199642.
PMID: 37795509
Introduction: The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside...
9.
Urrutia J, Anderson B, Belouin S, Berger A, Griffiths R, Grob C, et al.
J Psychoactive Drugs
. 2023 Sep;
55(5):523-538.
PMID: 37747281
As individuals and communities around the world confront mounting physical, psychological, and social threats, three complimentary mind-body-spirit pathways toward health, wellbeing, and human flourishing remain underappreciated within conventional practice among...
10.
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, et al.
JAMA
. 2023 Aug;
330(9):843-853.
PMID: 37651119
Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of...